Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clini... (utions for drugs and vaccines currently ...)

Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials

Date:12/11/2012

utions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching FDA-approved Phase 2 clinical trials; and with its oral exenatide capsule (ORMD-0901), currently approaching Phase 1b/2a trials, the results of which are expected in Q1 2013. The Company's corporate and R&D headquarters are based in Jerusalem.

The Company's fact sheet can be viewed here.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the projected commencement dates for our upcoming clinical trials, timeline for submission of the IND application, or when results are anticipated. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following fact
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
2. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Post Your Comments:

(Date:5/22/2013)... 22, 2013 STEPh, Inc., a full service ... of their web site ( http://www.stephreports.com ) ... About STEPh Reports STEPh Reports are ... Each STEPh Report assesses the competitive landscape by ... year, company, and specific key issues. STEPh Reports are ...

(Date:5/22/2013)... May 22, 2013 Upsher-Smith Laboratories, ... of its global Phase III clinical trial ... program for the management of epilepsy in ... USL255 is specifically engineered to provide convenient ... blood levels observed with currently available treatment ...

(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter. The Facebook homepage ... Says CEO Bruce J. ...

Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4 Medifirst Solutions, Inc. Announces Update To Shareholders 2

[0] Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site [0] Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures [0] Medifirst Solutions, Inc. Announces Update To Shareholders

... CARSON CITY, Nev., Dec. 21, 2011 Denali Concrete ... has commenced patient enrollment for a phase 3 clinical ... administered orally, in patients with moderate-to-severe Dry Eye Syndrome. ... States, Europe and Israel. The randomized, double-masked clinical trial ...

... and BEDMINSTER, N.J., Dec. 20, 2011 QRxPharma Limited (ASX: QRX ... of Intent (LOI) with Actavis Inc. for the formation of ... acute pain marketplace. MoxDuo IR is a patented ... Inc. is a subsidiary of Actavis Group, hf a privately ...

Cached Medicine Technology:Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study 2 QRxPharma Announces Strategic Partnership with Actavis 2 QRxPharma Announces Strategic Partnership with Actavis 3 QRxPharma Announces Strategic Partnership with Actavis 4 QRxPharma Announces Strategic Partnership with Actavis 5

Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study QRxPharma Announces Strategic Partnership with Actavis

(Date:5/22/2013)... Francisco, CA (PRWEB) May 22, 2013 On ... costing $6,500 or more on average, a funeral concierge can ... funeral, among other benefits. Funeral Financials announces ... the average household income in the U.S. having ... according to Sentier Research, the average funeral costs 12.6% of ...

(Date:5/22/2013)... TWITTER: @the_USO & @SesameStreet are proud to ... in the next 6 months! , Today, the ... came together to show their heartfelt thanks to those who currently ... for distribution to our servicemen and women. The group was ... and the USO as well as the success of the ...

(Date:5/22/2013)... 22, 2013 Zensah® Compression Apparel released ... article titled "Breast pain while running affects ... could help." According to the article, a British ... substantial amount suffer from breast pain while running but ... the issue. , Zensah emphasizes the importance for ...

(Date:5/22/2013)... Angeles, CA (PRWEB) May 22, 2013 ... , hosted by Patricia O’Laughlin Psychotherapy in the ... seeing people of all ages as progression to ... children of all ages into parenting therapy has ... O’Laughlin emphasizes. Patricia O’Laughlin Psychotherapy now specializes in ...

(Date:5/22/2013)... Scottsdale, AZ (PRWEB) May 22, 2013 ... spend the next year participating in an intensive startup ... deliver valuable products or services and create local jobs ... . , Each year the Edson initiative offers approximately ... funding, office space, mentorship and training to launch their ...

[0] Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge [0] The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC [0] Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners [0] Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort

... The Partnership for Food Safety Education Tackles Four Common ... WASHINGTON, Aug. 26 Recipes can be ... food safety -- sometimes with sickening consequences. September is National ... (PFSE), in cooperation with the Food and Drug Administration, the Centers ...

... explain why many patients respond poorly to chemo ... -- Finnish researchers say they have identified a ... , The investigators used a three-dimensional imaging technique ... flow and glucose consumption -- a measure of ...

... , , HARRISBURG, Pa., Aug. 26 ... of Senator Kennedy of Massachusetts: , , "I was saddened ... the true giants of American public life. It marks the end of an ... , "During almost five decades in the United States Senate, Ted ...

... , , KANSAS CITY, Mo., Aug. 26 ... n cer Ce n ter ... which supports the nation,s foremost cancer treatment and research network, has treated its first patient ... its new KCCC-Shawnee Mission office. , , KCCC is the only ...

... ... ever-larger role in public relations practice, many PR professionals are turning to BurrellesLuce for valuable ... ... As social media assumes an ever-larger role in public relations practice, many PR professionals are ...

... LINO LAKES, Minn., Aug. 26 ... regional construction firms have been recognized by Minnesota Laborers-Employers Cooperation ... in 2008. , , Begun in 2007, ... safety performance and proactive approach of Skilled Construction Union Laborers ...

Cached Medicine News:Health News:MythBusters: Dishing Up Food Safety Fact From Fiction 2 Health News:MythBusters: Dishing Up Food Safety Fact From Fiction 3 Health News:Blood Flow Mismatch Seen in Pancreatic Cancers 2 Health News:New Precision Radiation Treatment System Fights Cancer 2 Health News:New Precision Radiation Treatment System Fights Cancer 3 Health News:PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 2 Health News:PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 3 Health News:Twenty-Two Regional Construction Firms Recognized for Their Commitment to Worker Safety 2

MythBusters: Dishing Up Food Safety Fact From Fiction Blood Flow Mismatch Seen in Pancreatic Cancers Pennsylvania Governor Rendell Issues Statement on Senator Edward M. Kennedy New Precision Radiation Treatment System Fights Cancer PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce Twenty-Two Regional Construction Firms Recognized for Their Commitment to Worker Safety

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Promazine, Urine Prolactin Macroadenoma Prograf Proloprim